Vincent K. Lam, MD
In a recent phase II study, the next-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) lorlatinib induced an objective response rate (ORR) of 90% in treatment-naïve patients with ALK
-positive non–small cell lung cancer (NSCLC).
OncLive: Please provide an overview of your presentation.
I discussed the latest developments for patients with ALK- and ROS1-positive NSCLC. We are seeing that treatment development is much better with the ALK-targeted therapies compared with ROS1
. Overall, it is an exciting time.
What potential is there with entrectinib as a treatment for patients with ROS1-positive NSCLC?
falls behind compared with ALK
development. It is important to keep in mind that not all ALK inhibitors work for ROS1
-positive NSCLC, such as alectinib. In terms of the ROS1
data, the furthest along is lorlatinib. The phase II trial in the ROS1
cohort showed good response for patients who have been previously treated or are treatment naïve. These results are similar to what we are seeing with ALK.
... to read the full story